Earnings call transcript: Health In Tech misses EPS forecast in Q2 2025

Health In Tech Inc. (HIT) reported mixed Q2 2025 earnings, with EPS of $0.01 falling short of the $0.02 forecast, but revenue surged 86% year-over-year to $9.3 million. Despite the EPS miss, the stock rose 16.38% in aftermarket trading, closing at $1.24, signaling strong investor confidence. This optimism is driven by significant top-line growth, expanded strategic partnerships, and the successful deployment of AI-powered platforms, positioning HIT for continued growth in the vast small business healthcare market.

Analysis

Health In Tech Inc. (HIT) delivered a mixed but fundamentally strong Q2 2025 performance, highlighted by an exceptional 86% year-over-year revenue surge to $9.3 million, which overshadowed an earnings per share (EPS) miss of $0.01 against a $0.02 forecast. The market responded with significant optimism, driving the stock up 16.38% in aftermarket trading, indicating that investors are prioritizing the company's aggressive growth trajectory and strategic execution over the earnings shortfall. This top-line growth is directly attributed to an 87% increase in distribution partners and the successful deployment of its AI-powered eDiP platform. The company demonstrated powerful operating leverage, with adjusted EBITDA increasing 134% to $1.6 million and pretax income more than doubling to $800,000. Financial discipline is evident in reduced sales, marketing, and R&D expenses as a percentage of revenue, alongside a strong balance sheet featuring $8.1 million in cash, positive operating cash flow, and a minimal debt-to-equity ratio of 0.01. The forward outlook remains robust, supported by a forecast of 49% revenue growth for FY2025 and key initiatives like the upcoming launch of an enhanced underwriting platform for mid-sized employers and new strategic partnerships aimed at disrupting the trillion-dollar small business healthcare market.

Key Decisions for Investors

• Given the market's bullish reaction, investors should prioritize the company's 86% revenue growth and expanding partner network as the primary indicators of its health, treating the EPS miss as a secondary concern for now.
• It is crucial to monitor the company's ability to maintain its significant operating leverage and translate explosive top-line growth into consistent GAAP profitability in subsequent quarters.
• The successful Q3 launch of the enhanced AI-backed underwriting platform for mid-sized employers is a critical near-term catalyst that could significantly expand the company's addressable market and validate its growth strategy.
• While the stock has strong momentum, investors should note it trades near its InvestingPro Fair Value; the potential to reach analyst price targets of $2.05-$2.50 hinges on sustained execution and converting its strong pipeline into realized revenue.